CHK and MEK inhibitors team up to trigger cancer cell suicide.
Prendergast
George C
GC
Lankenau Institute for Medical Research Jefferson Health System, 100 Lancaster Avenue, Wynnewood, Pennsylvania 19096 USA. prendergastg@mlhs.org
D000470:Alkaloids / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D000071877:Checkpoint Kinase 1; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology*; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; D015398:Signal Transduction; D019311:Staurosporine / Q000031:analogs & derivatives
D000470:Alkaloids; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D047428:Protein Kinase Inhibitors; C054852:7-hydroxystaurosporine; D011494:Protein Kinases; D000071877:Checkpoint Kinase 1; D020930:MAP Kinase Kinase Kinases; D019311:Staurosporine